KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBITDA Margin: 2009-2025

Historic EBITDA Margin for Ionis Pharmaceuticals (IONS) over the last 17 years, with Sep 2025 value amounting to -102.21%.

  • Ionis Pharmaceuticals' EBITDA Margin rose 888.00% to -102.21% in Q3 2025 from the same period last year, while for Sep 2025 it was -35.07%, marking a year-over-year increase of 1105.00%. This contributed to the annual value of -67.37% for FY2024, which is 2246.00% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported EBITDA Margin of -102.21% as of Q3 2025, which was down 303.23% from 50.29% recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' EBITDA Margin peaked at 50.29% during Q2 2025, and registered a low of -136.95% during Q4 2022.
  • For the 3-year period, Ionis Pharmaceuticals' EBITDA Margin averaged around -64.96%, with its median value being -87.45% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 34,008bps in 2021, then crashed by 18,709bps in 2022.
  • Quarterly analysis of 5 years shows Ionis Pharmaceuticals' EBITDA Margin stood at 50.14% in 2021, then tumbled by 18,709bps to -136.95% in 2022, then surged by 13,507bps to -1.89% in 2023, then crashed by 4,702bps to -48.91% in 2024, then skyrocketed by 888bps to -102.21% in 2025.
  • Its EBITDA Margin was -102.21% in Q3 2025, compared to 50.29% in Q2 2025 and -111.59% in Q1 2025.